title: Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy.
abstract: OBJECTIVE
  The objective of this study was to investigate the predictive value of common genetic alterations of PI3K/AKT/mTOR and Ras/Raf/MAPK pathways in patients with locally advanced cervical squamous cell carcinoma (LACSCC) treated with cisplatin-based concurrent chemoradiotherapy (CCRT).
  
  
  METHODS
  Patients with LACSCC, treated at a single institution with CCRT were eligible for this retrospective study. A total of sixty pre-treatment tumor biopsies were retrieved. Somatic mutations were detected by pyrosequencing and CNV was determined by quantitative realtime PCR. The association of genetic alterations with clinicopathological characteristics and treatment response were analyzed.
  
  
  RESULTS
  Patients without genetic alterations (mutations or amplification) of PIK3CA had a significantly higher response rate than patients with these alterations (p=0.006). In the logistic regression analysis, PIK3CA genetic alterations retained an independent factor in predicting response to CCRT.
  
  
  CONCLUSIONS
  Somatic mutations and copy number amplification of PIK3CA were associated with response to CCRT in patients with cervical squamous cell carcinoma.
authors.affiliation: Department of Radiotherapy Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, PR China.
authors.forename: Juan
authors.initials: J
authors.lastname: Wang
authors.affiliation: Department of Radiotherapy Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, PR China.
authors.forename: Yan-lan
authors.initials: YL
authors.lastname: Chai
authors.affiliation: Department of Radiotherapy Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, PR China.
authors.forename: Tao
authors.initials: T
authors.lastname: Wang
authors.affiliation: The National Engineering Research Center for Miniaturized Detection Systems, School of Life Sciences, Northwest University, Xi'an, PR China.
authors.forename: Jin-hui
authors.initials: JH
authors.lastname: Liu
authors.affiliation: The National Engineering Research Center for Miniaturized Detection Systems, School of Life Sciences, Northwest University, Xi'an, PR China. Electronic address: daipg@nwu.edu.cn.
authors.forename: Peng-gao
authors.initials: PG
authors.lastname: Dai
authors.affiliation: Department of Radiotherapy Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, PR China. Electronic address: liuzmail@163.com.
authors.forename: Zi
authors.initials: Z
authors.lastname: Liu
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000628:therapy; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000627:therapeutic use; D058534:Class I Phosphatidylinositol 3-Kinases; D056915:DNA Copy Number Variations; D005260:Female; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics*; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000235:genetics* / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents; D019869:Phosphatidylinositol 3-Kinases; D058534:Class I Phosphatidylinositol 3-Kinases; C484760:PIK3CA protein, human; D002945:Cisplatin
keywords: Cervical carcinoma; Chemoradiotherapy; Genetic alterations; PIK3CA; Response